Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
Read More
Tag: Venclyxto
AbbVie’s Venclyxto gets NICE blood cancer backing
Oral B-cell lymphoma-2 inhibitor approved to treat chronic lymphocytic leukaemia
Read More
AbbVie’s Venclyxto shows promise as AML treatment
The drug is already on the market to treat chronic lymphocytic leukaemia (CLL)
Read More
Venclexta/Venclyxto combo extends myeloid leukaemia survival
Roche also reported that safety for Venclexta/Venclyxto with azacitidine appeared consistent with the known safety profile of these medicines.
Read More
AbbVie, Roche present positive Venclyxto results at ASCO
Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.
Read More
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Read More
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read More
AbbVie’s Venclyxto hit with NICE rejection
Draft guidelines do not recommend NHS use of AbbVie’s Venclyxto for treating relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read More
AbbVie’s Venclyxto now available through CDF
AbbVie’s Venclyxto is now available on the National Health Service in England via the Cancer Drugs Fund for patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL), on the recommendation of the National Institute for Health and Care Excellence.
Read More
NHS patients denied access to AbbVie’s Venclyxto
Patients with certain forms of chronic lymphocytic leukaemia are unlikely to get access to AbbVie’s Venclyxto on the NHS after cost regulators rejected funding for the drug.
Read More
AbbVie’s Venclyxto OK’d in Europe for CLL
Patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL) have gained a new treatment option after the European Commission issued a green light for AbbVie’s Venclyxto.
Read More
Eight medicines win CHMP nod
Eight medicines have taken a big leap towards being approved in Europe having won the support of the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
